<SEC-DOCUMENT>0001193125-12-446939.txt : 20121101
<SEC-HEADER>0001193125-12-446939.hdr.sgml : 20121101
<ACCEPTANCE-DATETIME>20121101172034
ACCESSION NUMBER:		0001193125-12-446939
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121101
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121101
DATE AS OF CHANGE:		20121101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		121174395

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d432419d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): November&nbsp;1, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>810 Seventh Avenue, 35<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, New York, 10019 </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
489-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NONE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;1, 2012, Delcath Systems, Inc. (the &#147;Company&#148;) issued a press release announcing that the U.S. Food and Drug
Administration (the &#147;FDA&#148;) assigned a Prescription Drug User Fee Act (PDUFA) goal date of June&nbsp;15, 2013, for substantive review of the Company&#146;s New Drug Application (&#147;NDA&#148;) for its proprietary chemosaturation system
with melphalan hydrochloride for injection. The FDA accepted the Company&#146;s NDA submission for filing on October&nbsp;14, 2012, and designated the NDA for standard review. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following exhibits are filed herewith: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated November 1, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;1, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: <U></U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, General Counsel</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated November 1, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d432419dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g432419ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DELCATH ANNOUNCES JUNE 15, 2013 PDUFA GOAL DATE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR NEW DRUG APPLICATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NEW YORK, November&nbsp;1, 2012 &#150; Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the U.S. Food and Drug Administration (FDA) assigned a
Prescription Drug User Fee Act (PDUFA) goal date of June&nbsp;15, 2013, for substantive review of the Company&#146;s New Drug Application (NDA) of its proprietary chemosaturation system with melphalan hydrochloride for injection. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA accepted Delcath&#146;s NDA submission for filing on October&nbsp;14, 2012, and designated the NDA for standard review. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company seeks approval to market and sell its proprietary chemosaturation system with melphalan hydrochloride in the United States as a treatment for
patients with unresectable metastatic melanoma in the liver. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>About Delcath Systems</U></I></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath&#146;s proprietary system for chemosaturation
is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body while controlling the systemic exposure of those agents. The Company&#146;s initial focus is on the treatment of primary and
metastatic liver cancers. In 2010, Delcath announced that its randomized Phase 3 clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study&#146;s primary endpoint of extended hepatic progression-free
survival. The Company also completed a multi-arm Phase 2 trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT&reg; Delivery System with melphalan hydrochloride for injection in
April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT with melphalan hydrochloride for injection in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company
has not yet received FDA approval for commercial sale of its system in the United States. The Company&#146;s NDA has been accepted for filing and substantive review by the FDA. The Company is seeking approval for its proprietary chemosaturation
system with melphalan hydrochloride as a treatment for patients with unresectable metastatic melanoma in the liver. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For more information,
please visit the Company&#146;s website at www.delcath.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news release contains forward-looking </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the contents of the 74 Day letter and our ability to address the same, timing of completion of the FDA&#146;s review of our NDA, the extent to which the FDA may request additional information or data and
our ability to provide the same in a timely manner, , acceptability of the Phase 1, 2 and 3 clinical trial data by the FDA, FDA approval of the Company&#146;s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting
sales, if any, in the United States, patient outcomes using the Generation 2 system, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system
and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory
agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into strategic partnerships in foreign markets including in key Asian markets and timing of the same, the initiation of clinical trials in key
Asian markets with the CHEMOSAT system for doxorubicin and timing and results of the same, approval of the CHEMOSAT system with doxorubicin in key Asian markets, patient outcomes using the CHEMOSAT system with doxorubicin, uncertainties relating to
the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others,
are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact Information:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Contact:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Media Contact:</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Doug Sherk/Gregory Gin</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Janine McCargo</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">415-568-4887/646-445-4801</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-688-0425</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g432419ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g432419ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P$$`P$1``(1`0,1`?_$`,L````&`@,!````````
M```````&!P@)"@$"`P4+!`$``00#`0$```````````````$$!0<"`P8("1``
M``8!`P($`P0'`0H.`P```0(#!`4&!P`1""$2,1,4"4$B"E%A,A5Q0B,S)!87
M-/"!D:&Q4F)R1"7!T?&"PM)#TS65-C='&#@9&A$``0($!`0#!0(*!P@#````
M`0(#`!$$!2$Q$@9!41,'87$B@9&A,A3!T?"Q\4)28G*B(Q7A@K(S0S06DM)3
M@Z,D)1=C1$7_V@`,`P$``A$#$0`_`+YMJE%8&KV*::$346A8&:ED$E0'R5%H
MV-=/$DE`+L?RC*H`!@+L;8>@Z*=I#CJ&#+I*4E'O,:'9M(*T?F!1^$4:9?ZI
MGFE'3,Y&)8"XZ*H1<],Q;=556_@JJWBI9RP345`DR!`44(@`FV#;<1VVUZB;
M[&[<<IT.JJJH*4A)_P`.0F`<,,N44D[W2O#3JFQ34I2DD3/4F9&6,C+W1UO_
M`/5-S6^''[CAM\/XB_\`A_YS]FLO_16VY?YNK]S?W0#NG>2/\M2?]3[X47''
MU6G()G-MOZL\6L5SU9.Y2]<%`LUE@IU-IL`+"T//KRC!18H]2B=,2CMMIG7=
MA[26":&N?14_FZPDI/GHD1&RG[J7!#P-92LE@G'03/XX^^+47!#W!N/'N%8M
M7R-@V=<>N@W"$=>Z!8$R,KA1I9<ACI,YIAT!5JY\LPMW:6Z*Y0Z"`[AJBMU;
M3N>T+C_+[D@*2O%+B9Z5CF)XRX1:=AW#0;@HS66]6G3@I)S2>1A]1!W*`]1Z
MCXAL/B/00^[7-@2PG.)V6G`F<;:6"!H@A$^1^1Y+#F!<SY;AF3.2E\:8LO5Z
MBXZ1,L5A(2-6K<C-LF3TS<2KE:N7#(I5!((&[1'3ZTT:+E=Z6VO+T,U#Z&\,
M_49<H8W*I71T#]8T`7&V5$`Y8"*2C?ZJ3FRY21(CQ[XWF6=BW20(*N0@(5RZ
M5(BB40_.MS%!50-]@\0^`:]+GL/M@MJ2FKJBXDY>@":3XI$4L.Z%^EJ#%/IU
M)&!QDJ0X$1>FQ[,25AH]0L$RW;-)B=K$!-2K5EY@-&TA*Q+1\[0;><8ZWDI+
MKF*7O$3;!U$1UY<>:2Q4NLMJ*FD+*03+))EPB\*9:W&$*<P<*`3YD3YF#CK&
M-\#1!`T00-$$#1!&I^A?NW#?]&L5"<AS,$P!,\(8]RU]Q/A]PA/$,^2>8H?'
MTY8XYS+5JM^AE):Q3\:T7*V7<1K",9K@8A7!P)N<Y`[M3]CVE?=R!9M%,IQ#
M9$R"!+QF8@[MN"TV73_,Z@-J7D.)\H(7!+W,N/ON*/LLEX]L+TM7\0NJTQE[
M-<('^74)EU94)1=NE$L3N'#LX()11S',?8-S!TWU(;KV+==GE@7M37U#VN24
M'41IEFHY2GPAM8-SV[<!?:H$N)0T,R)3G!/]W3G+?O;VXF&SWC.K56X6Q3)%
M2I32%N7YH$"=C/MYE=XZ7/$.&[T%T2190(/=VCN/36_M[M>EW?N#^65ZU(:Z
M;BYIEJ&F0PGA&O=E^J=OVHU].A*U]5*`%3D<#G+'A$&7`_ZA[EWRRYA8&XZV
M/"F"H"N91NS6"L,S7U+H>;CH,K9=S(/(P'\HLR]4D5,.WS2F)X]-6CNKM#8+
M#MRIOE-45*GVFB4A6C22)9R$Y>4<-M_N)=;M=V*!YBF2TZX$DIUZ@,<IF4_.
M+C8!U^[??]`]-@_1MKSU%Q1MH@@:((&B"!H@@:((&B"!H@@:((&B"!H@@:((
M3_**PM\:9'<%[-T*';U2"<0`O<G7I%3<P_JD^7J/V:WV\:JQIO\`^9/]H0WJ
M5!-.Y^P?[)CR"+&J*\W9G`#NLK8+(Y*!!#Q<S$@L(D'P$F^VP_9KZ$,20PVD
M@%6A/XA'D%Q1+JS^NK\9CT"N$_LF>V]DSAYQHR%DKC1!3^0KSA''EJN,Z[GK
M*B[D['/5EA)2,@L5G*IMTCG=.CG*!$P*7<`VVUY)W-W)WC;MQUE)25BQ3M53
MB$)"4F24K(`RX`1Z#L>S=MU-GIJEZG"GG&$*4=2L2I()X\XKY^^E[2^._;YG
M,;9;X^+3:>%,K2TE6'M1GGYI9S0K@P;(OFZ$=+JCZEQ!3;98PHD5`3(J%$FY
M@ZZMOM=W`K=VL5%LNQ!NM.`K7(#6CE(`"?E%>[ZVE2V%U-90"5#4"4I_*H<!
MQ]L(-["/("RX/]RS"4)&R+A&KYU7>8@ND2!S$:RA)MFY/5W#E'?91:)GR)*)
MG$-PV$-]A'4MW9M3%VV=4N*`ZE,D.),L0D8$`Y@8Y"&&P;F]0[B99'RU"M"A
MPGE.647;O<U]T?#7MKXRBY^X,'-YRI=_6M<98HB'9&LA87#-(@NI:9D#D43@
MZM&J*%!=T<HB8P]B8&..VO-&Q]C7/>=6:>F/2HF0"ZZ<DI&<N:CP$79N;=%'
MMMA*E_Q*QR?31Y'CX14<MGU&ONDY5M;HN'XG'=08][I\TIU3Q6YR1(LHOYA3
M!_).ED72Q6I`W%4R28'VZ!KT&QV>V+04J%5SJGBK_$6Z6M7DF7#+QBHG>X^Z
M*I9^CZ<AF$H"B/.%8XS_`%/O+*BW&+8\JZ)2<N4'U23&RO:9!#0+[!H>I*F\
MDF4?YCN-E'3!(#B9JH*0GV$H&[MM1M\[)V2JIR_8776'0GTI)ZB5JE@)F1$X
M>6[N?<Z=V5W2ARG!$RD`%,_+,\Q%J#E]G*@YG]JGD?G3%\\%AH>1>)F3+%5)
MMB;RU7#2:HTL@BF<I]C-GK1TH9!PF;8Z:R9R#U#5"[8M=7;M\T=LKDRK6;@T
ME0E*1#@RGX<8M2\U;%;M2HJZ96IEVD6H'S2<_&/,'H4:I,77'D(B4IU92]TF
M+(`B.PA(6:':CN`=3=Q5>OP'7N.M<Z=,M2L2&W<_V%1YB8;2X^V@`?-R'Z28
M]7/D5RAQ'PDXR/\`.V:I<T13:/6(%J#9FGYTM8)M=BW9P];@V9?F<RLL[`$T
MB^!0W,;8H".O!%GL-?N2^)MEK1_'=43AP$\2?`<X]5W"Z4EEMAKJP@-)0!+B
M3+`#Q,4J\\?4Y\YKU99%?!E:QG@ZDBX,>(C9BOI9!M/Y>F<00/,2KYQ'QY'B
MJ8=RA$`,D0QA`#"``.O3%G[*;79ITBXJJ*NK_.4%%L`\4C`ZI<_"*6J^YNX'
M7-=%TFF)F25IFH#AF1G!`QG]2?[DL9:(%O:[1AF\Q$C881E(,WN.&4(L2->2
MC5L\,T=QLJH8CA-LJ80,("4!#3RX]EMHO4ZQ1MU#52A"B)K*@J0)R(\(T4W<
MO<Q>`>6P4&0P0!F1XF+P7+WE"3BQPXRMRD5BF$\ZQUC,EU8UYZ_4CV$W,.D&
M7H8L7B::RR2+AT]`-R$,;M#H`Z\P[>L:+]N:FLBEJ0RX_H*DXD`$XRB[KK=O
MY995W58FXAI*I<)D"*;:WU"?NWYT7=$P/ABIQC=P`JMVU,Q#9<C.&93B':F2
M2?\`I$G8$$P!W]A>X?AKT8UVA[?6P`7&L4J6'J=""3,X2&(PY^^*>_\`86\*
MU.JWT[?35B"&U*/M^^$>:_41^[%C6VKQN19#'+Q_$+IH3=%N&'$ZK(MS=Q!,
M@\\N0+),%U4?#Y!\=PWU*+[/[#KF"Y0(?0D9.(>+B1PGC#,]P=W4CNBI4WUQ
MCHZ>DD>9_+%J?@[[KK;FUP0S?R/B*DPHF7<#5:Z-[U3'+XTI7&ER@*@YLL))
MQCU0C9P\K<P@"*Q2J%*H3<R8]0U0FYM@KVWNNGLBWB_0U3J.FN4E:5+2DRX3
MQBT[!NMN^V)VYLIT53*#K!_2`/W10JYM^X#G/W%+W2\JYU2I:%BIU0<U"$0H
ML8>*C0BG<D6374<MUW#A47IG*8;&[MNSIMKU=MO:%KV73.V^VEU#;B@5=4SF
M1@`)<)Q0E^W%6;C>;K*]*2&DR``'.4X47@O[I_(_VWX3)$9@%CC5VCE!_!S%
MA5O4$O+K>HKS:0:1Q8XZ+QJ=NCVR9P.`[]Q@^X---S["M&]767;JBH#S(5(M
MD">'CY0ZL6Z;EMWJIMY3I>E\V,L8M#^_7DRQY#]F+C3?+BC%A;\K6_CW9[,:
M)`S:*;S<]C>PS\J,4W.8YP9`]6,"11$>U/;?5$]IZ%NB[AUM/3:@TPU4`!6)
MEU$IBT-\U3C^SJ9U\@ONELF64R@DD"*GOMV<CZ7Q$Y;XZY(WV+EK!$8KC[5+
MQU<A4R`_G[0ZAS-J[$`X5_9-&KA\?95R8!*F3?H([!KT#NZR.WRPOV2F5H2Z
MI`4J4](.)/PBIMOW%BT75N[N)*PVC4$3S(Y<C$D>1OJ5O<IM]ED)6C26'\6U
MX[IP#"K,Z$WMJD<T,?=%%[-3#]HY?ND"&[3*`D0!'<0#8-<=1=F-F,MI9K&Z
MEVIT^I:G@A)YZ0,O"<=)6=QMQ5+Y73N(8I?S1I!(\S$E7M;?43YBROGVA\>.
M94%2Y%CE.::56GY9I4<:MKP]J?IF)#1UEKI#NVKF.FWH`@1PBH!TEU2@8O9N
M.N%WQVAH*&UN7O;9=G3@EQM:@J:1B5).$](F3'4;9[B5E77HM]Z2G2LI2A:.
M*E$`3`RF<XN/]!VW'?80$/AUV'KT'KN`Z\]Q<,;:((ZF7F8R#8K2,S(,XQ@@
M7N6>OG";9NF78=Q,HH8I?AX`.^L6VW7W.DE"EGPA"I"1ZS(0@DARLPFP7,W+
M:5'HIF\LR["-?NVV_AW$731\M4-_L'4TWMJZ.9-#'QAO];3#\Z#_`$O,>-[^
M<6U7M4>^?;;C&K&,SD@#X_P3H$EOF^X!TRJ+=<*;U.M*#(S,9MU++QDDXPJ(
M>`?#H'3[--(W1G1!`T00-$$#1!"+\B)$D/@#.,J8Q2A'X?R4Z**@"*?<A3I@
MY.\"_M-C'V`=OAI[96^I=Z9O,FI1_;$-*\Z:)Y1S#*S[DF/(5\T7;9-=4`$[
MH075*0#%V,[5!50"]W7R@,H.XCU`-?0=`""A6&E)`]P,>0B@E)(.82?>J/6[
MX:Q9(?B-QCBBE2*5C@/$[8"I_NBB2CP8`!-^HE`=]M>`]Q*ZE_K5G$FK=/\`
MU%1ZXM`"+53)3@`PW_9$5O?JL<OUIGAGC=@5%\V6N5GR+*9$<QB1R"\CZS66
M";-!^LD(CVHR,DY41(([=PI&V^&KB[$4%0J[5=U=210I9Z:5<"L\!XQ6O=2J
M9^AI[9/^.ZZ5'F`./A.*VWL]5&5N?N><,XR*;*+J1>8(VVO2IE$?+A*FT<S$
MPN?<IQ3*W:-Q,._R_#5R=PWFJ78MQ+QDLL:!XZ\!XX'**XV>RNJW51RP"5ZC
M+PQG[0(6#WXLSV#+_N<9^0DW;HT/BD]:Q54V"ZPF;QL9$5]C*O3-TN[RVP/Y
MR:754-MW&$"^(`&F':JWHMVQ*9Q('6J075"6<EJ`)YX`9P[WY7NU6YGQCH84
M$CP](G+EC/*#1[9?N:YG]OO&]MC,*<-X7+$O>[$M+SV6W<'<GDV]8-T4&C.J
M(RD#%NVZ,+#*(]Q44U`(98QC'+WB(Z;[VV+:]WW%#UPN9ID-MI`:*DR&HDZI
M%8Q/.64;-N;FK-M4JT4-$'RZO45R,_*8&7A.&'\I)O+')W/^3<^J\:K7C)[D
MN:_F"5IM1H5M_E]A)J)%)).V0'AB=IWZ@>8MV@&Z@B/B.NJL+5ML-G;MJ:UN
MH#22`XIT!1ED<%'+@8@+I]=<Z]RO%*XT'9J*$I)2#Y2BSOQ>E+I2?IEN1C6\
MQM@A742PR_6X*-LD;(QCUO`34A"-V1$F3Y)LZ(S5D)9P)![0*/<.WQU2&X$,
MU'>RCZ"D+"N@HE*@H%4EF9/.<CSRBS[4I]GMG5*J`M+FES!4P923SX14QXQQ
MXRW([CI$'`I_S;.>'8TP"90A>UW?Z\F8I^P?,(`D$?O#;5]WM2F;)6.*S33.
M8\CH5B#SBJ+4@.5]*G@IUKW%29^8,6L_JN\BV!DCP^PLT=J(59Y_.U\D613B
M",E)Q*3*#BP<EW[U0CR"95/??M,(B'4=49V%HF^K7WC_`.P@H0.<E$DR\^/.
M+3[L5+J4T-`CY%*4H\L!+&(K?80X(XCYR<KKDUSO&ELN-<)4%O>GM%.Y=,FE
MQF9&7;PT.VE5F:B+L\,T57%PLB!R>:)"E,/:(@/;]VMU7/;.WFA:E:;C4NE"
M21,(!F3*>1Y2CEMBV2CO]V<=K\:=ID+(YD&4O*+NUN]K#V\;S!MJ]-\0\*(Q
M[4$1:+0-08U>5:G:;%:J$F:\6+E?.2%,![S+&$QNH[]1'S)3;\W=2K+]-<:@
M.2QU+4H&<PH2)RB[7=K[=JFY+HV@"J8TH2DB4N($\8^;GUR2X1\4L`-&_,5:
MO2>-Y4&4/5\5R\1_.4OD!Y6T4UF,3&51T"H38,RMR"HH[V:DZ"LH&^L]I6/<
MVX;OIVZ"FX).I;J24I;U$^K4,IF>48[@NEELMN`O$DLD:0@^HK"1D$F8,5NL
ME?5)P%-C'56XE<-*_3J\P[T(>0ODO&5Z+103#RV:XT>CQK=FW;E2`!$I9`O:
M`=H#\=7+0=BJFL>ZNX;BM3Y)GI&LJ4,2-2R??%<O=T6V1T;-1)33:?3J(09\
M]*0)^45GN6'*3+/,S.-JY"9J6AU+Q<F\<B="OPP0,(R@XM'T\-'QC$5G"ZC-
MNVZ%665665#83G\`U=-BLE#MVU(M%MU?3-H.*B"I:C\Q)&!D?=.*UNMVJ;Q<
M/KZS0*DG)((($XMO?2PT:%L/&'F"2R0K*8@K3F"%J\G%R;,CN,EXE+'D5ZQB
M[;N"J(.62GK3D.F8!(8!$!#;5!=]ZQUJ^VY3:E!3=+-)!/I(<.(Y'`2(QP'*
M+<[5,H=M%8'0%)54R(.,QH2<>?\`3$%WO[T/%>,/<@O%!P]1*ECBH5W&.+D2
MUBE0,97(-&6=0JSB0=DBXIN@S*Z<]Q?,4["G.(`)A$=6?VHJ:RKV:W57!QQZ
MH<<=];BBM7I5AZE$GRQCAM_T])1[@<9I$(;;#:/2E(2/E,\!+,XF)DOII^*/
M';-_&G/MLS3A;&.595#,S2&BWE^I4)9GL4P8UQ%8[5BZF&CQ1LU<+/.XR:8E
M()B@(ATU7?>R_7B@OM(S0U%0RVJDF>FXI`)GF=)$SX^R.P[9VN@KK8\Y6,,N
MK2^)%:$J($LA,'"%]^J++$5/@_QWHD!',(>&+G*(90T/&M4FC&-B:Q39-NTC
MV#5`"HM&;-NY*0A2`!2%*``'AJ&[&]1W<=74N>IWZ)1).),UB9)SF>/.)#N?
MTF;+3,(`2WU2`!@``DY`88914>]O[BQ_]T.7N&..3B1>0T'>+$=Q<):.`#/8
MZEP9"R%A58"?<@/'#;9(AS`($$_=\->AMWWY&V;!5WE,B\T@`))P4M0],_(Q
M4FWK0B]7EBUKF&%^I1&83QE%JKWE?:#X-<?/;RN66\#8E2QID/#"].<,+0QF
MIR1D+3&OIV/@I=A;?S.1>-I0[Q"0,L"Q2)G3<%`2[%^75#=MNXNZ[KO%JBN[
MZ7:2IUI*"D#20@E.@CERXQ:6\MH6*W;<7543);>;"/4DS*L<=?"1XQ4HX1QB
MLUS*XHQB!CD6>\A<2@44>IP,E<8AP/:(B`@/8EL&K^W6M(VU7:P"4TKTI\!T
MU915-A&J^TNC#^,WE^V.4>M0`=NP;CT``#P^'W>'AKP+/UR&4H]7Y)Q@G7FZ
M0U`K4G:IYR5!A'I`()]_[1VY-N#9BV*&V[AVH($)X]1W'PTXI*=ZLJ.@R)F,
M770RCJ*RB*2>L.4^3=U,S8,W3IL10QF%?;JG)`U]B)]B.9)3N!`SCM#<ZI]S
MB?H0OZNK$99H;#3264AT?,<`3^R<X@2[45;D@#*%VB.#$BJT*>=OS=J^,`"9
MO&0XO&R0B&^WFKNVAS;?ZNH=>[$M_P!U3DC]HPY3:DRQ(A)\C\8,C8T2"Q0[
MH+)&1A_4?F4""[.9BRD'N*Y4:`?SB%(/43HG/L'B7XZDZ+<5-<%"G<DD'@K$
M?&-+E&]3B;6,.1XR\B'%N.E0;O($5L*:6]?FE![#SB"!1%1D[*(!_O!$FPD,
M/S+E`?U@U!;@LWTW_=4<E,G$R&`GRED/A#RBJU+/1=^:'OAX!OX[!XZY<&8G
M$E*6$9TL$#1!`T00SSW`;&6H<(N55C$YDPC,%9$5[RCL)?.KSQMT'<OS"*_V
MZF]I,FHW)0M?G&I0/:%`Q$WYPM6:J6"00PK'V&/)N9`!F#$IA'O!!F814';Y
MTRHG`%-NT2E$0`/EZ[:]]'%3@6)`B0\^?G'D]L^M*C\DAAX19%K_`-3=S1IV
M-:UCJHX=P!$IU.H0-0@YQTSN$B]1;5^,;Q"$@JS-/>A6?&0:`<2>7Y/=O\NW
M35-N=F=LU%>NOJ7JIQ3JU+4@*0E(*B20))G($R$\8L5GN1?&*5-(RRSI;0$I
M40J9"1($\)D"(.\^\A\X\P<QRF4LTW"<R?E>Y+(,VB+=LHY53;$$$XVN5.KQ
M::HL(QL':5%HT2[!\1#?<=63;++:MN6L4=J;2U;VY%>(^8?GK)E-?-6<<3<K
ME<KU7!VXKU5*OD$B2!R3X<IQ<;^GG]J#(/'523YG<D*RYJ&2K=65*YB+'DLB
M9.?I=4E>\TW9;&V4`183MC;"5)!N(]R#0Y@.'<8`#SUW=WZQ=P=M69073-D%
MU<YA:AB$I/%(.7C.+A[>[5J*+_S5Q&E\@Z$D24$D2,QPPPB&GZB3AY>L$\X[
MCR"+7WZN&^100EEB+>U:K*PT7=6,.Q@['5I9[Y8M8]^X&+1=-R*F*#A-<W:(
MB4VK([07^ENVV46Q;B17T2"WI)D=!45!7BD!4I>$<3W#MCUOOBJP(<50U9"I
MIGZ2$@&?M!CJ?:F][:5]O6AR>$<C8=0S-AMU89*TP)H9Y'Q%TJ,Q-G(I*HM7
M<BU>,)6$>N2&6!$Q`.14X]ARE';6O??;)C=]0+I1U2J:X(`229Z'`G!.`\/P
MRC/:F]GK`S]`^T'J69T@?-B9YQ)[D;ZI2$FU(NN\?^&1`L<Y+1,/'R65+)&J
M1:;B7D$(])48BML&3]42*N`V`%]MPZZXBD['O4[2ZF]W&5,D%02TG$@#4<29
M2('`3CI:CN@I92BCMZQK6$3409$X9#QB5_WQK+(0/L\YF7L;2/BK'::[BB%G
M8^*2!M'I6*QVJJA--6*7XO3)O#JE(!MS"0H;B(ZX3M>RR_W$I@P5+:0\X059
MD)2O3.8X8?9'6;W>4ULQ\O2#BVVP1P!4M$Q[C+RBAEP#CB2G.#B)'F[R@OR#
MQB(B!0.H/I+&S>@7M$.I/X7KKU9NQW1MJY.@G3]([+P])BA["C_SU&WP%0V)
M<.!$6_/J>N(5]S!@O$W)/'E?D;.KQ^E)]CD&,B&:S^3;4&TE;E-/(,FZ2CA=
MI!R27F.1)U32-WCN`#KSWV0W%2VZYU5EK%H;%6@=-2OE#B<L_A%N]S;2_543
M-T92I8IUD+"?FT',B*CW`SG=F/@!FUOG'"IH&85?Q"E<N%3L(.7%7NE9=*I.
M#1K\T>Y0=(*-W2)%D5TSE424)X[;AKT!N?:]NWE:OY9<->>M+J,TJ&$QY\(J
M:PWRIV[5_54J@`29I.:DDS`/ERYQ8YQ3]2GR8Y%YOP7@K'G&W%U&D,J9.H%&
M?S\M,V&QN63&<G&;6PN(IB1\BV!1"),NHB9<JG:)-QW#5,W#LM8[+:W[Q7UC
MZU,,K.G0$IPR!/$&>/E%DTW<JYW6L9I*6D0E;KR02<9C&<A#6/JCX+)C7FQB
M"?LI)13&,AA%A$8]D%B+C`A/LYI\K;8]J8O\*A,*K*%64('[44#%'82[:G>R
M#]!_IFJ:8T_6IJ5%8GZ@D@!&&93A(<,(A^Z;50F],/N$_2J:`2)3053,_`80
MROVD>0?MI\<K+DR[<]<.6'*5P1"+/AXR=+8Y!JD4W134/*I.:Q(/&K%&P.'Y
M$S-GJI5.Q/<I0#?74;]M&\[NVQ1;5JD4[102[-9;)PE@H8Z?#GC$+M2NVU;'
M7JC<#74?2?X<QJ2#^J#@/.&O^X_RJH_,[EK=LYXRHJ^.<>/HBK5&F5%RC&LW
M+"!J485@W5691*:+"/,_6,HJ""8#Y13`4QA'4ULZQ5NVMOLVJN>2\_BM1!*L
M2K'U$S.?MB,W'=J6]70U=$C13!)D)2`Y'#C%NWZ6B/3;<%<J2903!27Y!V/O
M$I0`1_+X"$:%*H;8>X"`00#[`#7GSOPX5;D90,A2(`'*:C^!BW.UB4BPN*XF
MI5/QP$5N?J`(BQ17NJ\@EI]FZ;(S4)CB3KIG!-B/8`U:*DD[:'Z><U]0F<@[
M"/:<-MM71VH<"]BTJ6"VL(+FL<02KX3BMNX`>&ZGC4@I:*1H//#[(YO;(]Y/
M*WMM4'(V*J7AVIY:C,D6F/LT,6;E)2(=PUH4;DB%$CG8+)_F,7((>4(I;`H5
M0GRFV,(:T;W[<T&]ZJGKGZAYE;"2%!/Z/V@<LN,9;9WA7;8IS2--H=0XL&9S
M!.`.<3)_5$726F..7`AC9VS2-M]BG[5=)^'8J*BV8R(4JK"_;-?/.=P+5H_D
M5$R"<3")0ZCOJO.QU.VU=[LZSZF$,I2"HXRUD"0_6E,CPCLNZ#KCM!0!02"M
M9)'F!]\HC5^FA@$Y?W,64FLGYH5K!N2'Z(F(4Q4W$D$6P34$1`=CI@)NT>@A
MKM.]3I1LQ21@IRJ;GX@`RCF^VB`O<VK\U+*Q[,I1:'^H8GBP7M79U2(H1):>
MG\8P*7<`#W@[OL&JNF4!`=CBV0-L/CJD>S[(=WW2N2F4I<5[FS,Q9?<!26MJ
M/@"6HH'[X$45?;2B33'N"\-V1#I;FSS1WP@MMMV1[A20,`=![C@#?<H#\0#7
MJ3>BBWM.Y+&9I7)>!)E\1A%&[:(7?J(92J1/R!!_)'IY/^1N(XO,\?@-]:`1
MR;+,2OV4*+-T9N<JB(NT6WKRIF;E>*M0\P";[;=!$!Z:\0-VFO7;UW,)'TZ5
M2G'I]=?2IJQ0J)ZZL1#0N6]QD[CD."Q7`"HY1C%F1%V:/<(.[-+G\IKYQ2]#
M>@;G`=A#]??75[:HVZ6B7<WI`<X:UCA=>Z`RAP@.J1Q.Q4U3703?V-_L51%O
MV%?V2PG1`ZXF6,!3%C&(#V]P]$T@#;YAU!Z:K<MQ4#,4R<1C@$>'ZT.ATJ%J
M0,W/C#+YOE+FVPOUG4;,_DS9(?-+'0,41=NU2'\)'"QDEW!P`/$RAM=6Q8+5
M3C3HU+_7(^V(Y594.G6B83X0O>$^6;R;E&=2R@$>/YJ8K2.L[9$K9L+E3<A6
MDNV']B4BH_*50``.X?F\=0MXVXFG1]71*U`<!C[,(=4]>5+Z;PQ,)KR:QBMB
MFYP^1*:4\=&3$D5X@1F4>V'LC01>""1DP*";5\F0QP`-@`0-]NGU@KOYG2+M
M;^"PGCRC56-=!P/MY3G$B>-;DVOU'KEK;&+_`+VCD%7)"CN"#XA`2>H;[[_L
MG9#!^C7&5U,:2K733R)(\N$2C#O6:"^,H/@::I,Q.-L#2P0-$$)QEC&5&S7C
MJXXFR3#M[#0[Y!O*[:X%==1!.6AGP%!TR541.FJ1-<"@!MA`=OCK=0UE7;JQ
M%=1314-JU)4,P>8\8T5##%8PJE?`4TM,B#Q!X1%^7V'_`&J@(4H<6ZKL4I"@
M`R\V;8"``%#?\P$.FVNZ5W3WZL`+K73_`%1_NQR_^A=K9?2)EYG[XV__`$0^
MU5M_^+53W'XC+S@#XB.VX2'3<!'?[=![I[\(_P`XY_LC_=A/]!;5.=*/>K[X
M=9@7V[N#?&5VC)X4XV8GI<XAVBG8D:^TE+`18H[^>E+3'KWC5QT_&B9,=0-T
MW=N>\ITW*LJ7$$_+,A(\)"6'G$K0;<L5J,Z&F:0OG*9]ZIGW0]$3HB._>B/W
MBH'_`![:YL-C#!6!B;]$PH_,((N1\:8VS!4):@Y2IU5R!3)M+R92LVJ+8S40
MZ(("4IU&KPBA4U2`8>Q4G:H01^4P:<T5766RH%70..M/#(I)!_I]L-ZJEI:U
MHT]4A#C)S"@#^'LB'B[_`$\?M87.:=3),,3E-%VJ*HQU$O<K`PZ(#\QDV[$X
M/2H)";X`;X=!U8-)W<W[3M);^HZ@1DIQ"5*\C@,N&&4<B_V]VH\[U>CTR,@E
M9`'.0\<S!AQ;[!7M@XHM4%<HK"CZSS=:DF,S#JWBY2EB;MI2,=)O6#[T>[1%
M19JZ2*<NX"7<.H#K56]U=[US:F7:E*$*200E($P1(\#F.4+3[!VM2NA]#2E.
MA05BHG$9&)*>1/'#"O*_&4AAW/-08WK'4K)Q$N_KKYRNW0<2,(^2?Q:XG:K)
M*_PKQ(J@!OMW%#7%VB[W"PUPN-K=6S6)G)7$:I@RGP,Y1TU?;J&[4JJ2X-!R
MG402E7&4B#\![H95CCV8O;9Q1?*CDZA<=*S`W:B3K.RU:=0E991:*FV!MVCU
M,JKTZ9SI'$=@,40WUTU9W%WK7TJZ*JJUJI7$E*@92*59@X<8B&-G[=I7Q5,T
M[8?2H*!'`C(^R)0G3=C(-'+!^@S?LW:2S=VQ=IH.&SMNN4R;ANX;.`.BLW5(
M80,0Y1*8H["&N%2E7]X@GJI,P4X2/A'2'2H%*I$'`SEC$/>:?8:]L/-UI?W*
M8P4E1YN565<R9\76)U2&+YVN83KN5(MF1>/267,8>[RDTR=1V#5B6SNIOBW-
MAENK<6VE(2`XD*T@8`#(RCD:S8VV*ISJJIT(7C/22F<^>?PCNN._L?\`MR\9
M,DU;+F.,2OWN0:5(IR]4L-PMTC9%X.613522DF2*OIFQ':2:Q@*82CL`^&L+
MOW,WG>:)RWU-0/HW4%*TA.D*"LP<R<N<;+;LO;MLJA6TK0%0@S"BHJ*3X<H?
MKR-XQ8`Y94!7&7(;&M6R=4%'`O6S*?;)J.8F3\HR"<K"2*1TWT3()D-T41.7
M?8`,`ATURMEOMYV[6"NM+RVJDB2B@8$<B#@1YB)VXVVANK'T]8TEUGQX>1B)
MYM].1[63:4_,AQI>W*7F@H$2[R7**1("4_>!`;`@10R/ZH`*GATWUW1[Q[\<
M;^F0\WH`P(:`4.9U8_BCDQVYVOU"Z&58XE.O"%QD_8R]K"57;KJ<5:0U]*Q:
M,2$8R$PT1\MF7M*JHF60,!W*^XF54'J8VHT=S]]I`;57NX>`$A/*>GG#P;%V
MMJDFE1*7,^WC#X>,O%+C_P`/*$[Q?QWHD;CND/YQ]9G<-'NG#A-::D03([?G
M4>++*=ZJ:)0\=MBZY>]WN\;@J4UUV=4_4)`2"<Y`F0$@,!C$[;[7;[2R:6@:
M#3!5,@93EGB<X2/F%[<7#KG:A"&Y&XLC+3-UI,[:OW*+=J0-SBV:Q@.M'H3S
M$?4+QRJ@`;RE04*0WX=MQU([=W?N#:^H69YQII1]2")H43Q(/$<)2AG>=N6:
M_:571M*UIP"IR4!R!'`PR>A_3S^UU0K/#6MKBJT661@)1E,1K6WY`DYF+(^C
METW#0RK$B3,BY4UTRF[3"(#MKIZKNYOA]E3*:A+86)$H0$F7GC$)3]O=K,NI
M<#94M)F`I9(]V$/VY2\!>)G,]Q2EN2&+8C)!\=MY-I3BOW[UJG"(3'I/S$C<
MC-PB!C.RL4MQ$!Z)@'37(V7=.X-N=4VI\LA\C7IECIG*<P<IF7F8Z"YV"T7G
MI_S!H++7R\QY04N-'MD\(>(.0764N/.&(+'MY>0+JLNIZ/D9!RNI#/54UW+$
MR3MVJB!554BB/0!Z:<7C>.Y]PTOT=VJG'J74%:3+`C`$8#&4:;=MBR6A_P"J
MM[(;?D02.1S!\(7ODEQGP;RSQHYQ+GZHLKWCYS*1L\Z@'KUPU:JR,,MZI@Y4
M4:+(J"#58O<`".VX:BK3=[I8JL5MH<<9K0"`M.<E"1&,\",#$A<+=0W2F-+7
MH#E*<2#E@9S]AQB,VE^W?[1/'S*U3OU'PS78+(V/)QM.UV?AEK%*D@YIH4Z+
M=SYR:ZS3O0*H8``VX!N.X:[BIW3W%N]`NDJ*EQ=(Z@I4E1&1SX>V.>IML[2H
M*E#U,PA+Z5S21.8/.)+F>*,$7?(L;R(81,/-72.:>6RL[5ZH/EG;M!:E77:`
MH"17S-F`I%$0#8HCN41ZZXA=7=*:G-H<6M-,3,I&1/X>,=*:6C4]]:4)-0D8
M*XRAH>!6I;]R7LMIDMUTHI_9)XAECAVE<`Z&,CCF[]NXK<`*8NW@(!KJ[NKZ
M6P-TC&!)1.7&8QAC3)#U67EY1\.:%9/-7(I"CL7)DX^,>(5MHKU.DT0;%]9/
M2(DW%,%"F.<H#^MY90'65KT6RQFJD"X<91A43?J^B,N</)6F<$8$80U/?+P<
M,HZ1*!"+,TGL@[*.R:LA*K%245!-0^XF.<0('V;:Y8-WF[+-2-4LI3,HE/\`
MMZ=,L`(;9RMQ!6VL*SRU1T&;-FY5;$G218D+&NDGYDQCYMF1OL0BOGB4IA)L
M4P#N(;AJ>V[<G>LNVUDSR!X2AE7,)">NT!,0>G+P^8>([R0D#"YFJ_%+G47'
MYURR-35!05N[J(JKQQ`[A_6[Q^W31`-MW/)!TM."4N<_Z8R'\>AUG%0'V1]W
M">?]=CZ=A%U=Q@K&H9`##L4B,DV1=F!,#;`4H.#G$0\.X1T;IID-UR%MSU%O
M&,[:H=(@'V0O%NSGC*COABIVQI%D2;@HR8(+R+A#;Q\]-H144A#X[^&H6FM-
MQ?1J;:5TSD>8APJI81Z2K$09ZCD&HWED9_5IQI*H)F[5BIF['+<QN@$<-E`(
MLD(>.XAIM4T=;2*T/H('/C&QMUM:04GWP<?,+V_O";_;W%V_SMO'PVZ:TZ#*
M7J\XV3$Y80W*X&$+'*[TV]2``X#^/BG+T&3C<H"(H)HJ`3R_T!L&IV@,VI%Q
MI((X_P!,-',5:M/J$%7N^S'^2MOALXD/^\TZUJ&'6;]XA-2OT5>\QR`<@`(?
MT_R;UV$?XE\/4H;!MN`[;:3J+_XS?O$;!ED?>?O@".__`,?9*VZ>+E[O_?\`
MG#2:C_Q6OA&E10#B@S]L8Z!X8_R2'W`Y?``?X-PUF%`#^]9^$*%(_0<]F4`3
M%V$HT')8`.PB`.'NP[#N&_S`(AI-6,PZU^[":T@S"%>V<XR!AW[@H&2S;_$S
MI\/@(CMVBIL``(^&L5&>!=:_=A>H#FD_&,;"/7^GV2_[SM]MX[]`\W8.N@*D
M)!QCW)G[\XP);)F4.3\)P#&'P-0<FA\>CE\(_'KW>9N`Z4JU)TJ<9(_JQF%8
M22E<O'/\D8[N@@%`R5L/0>YU($'X#M\@CN7?K^G28#)UF7]6%2A.929^9^^-
M@,(]1H&20'?Q*[D0-L/P$W01#[O#2ZS_`,5GW)'V0*"`9Z5^R`)BAXX_R3UW
M\'#[_K%TA.K-QD^Q,(7`G)*_;A^*!YA=NT*#DGMW`=O52!0$0^.P";?2<I.,
MB7@F,2X%"2D&7MC43EV_]O\`))M]_P#:Y`P[#T'J8.@:R*CQ<8]R?NA04D:0
M@R'G&`$`#8N/\E$\.OJI#P#KL`[;AL.DU$B0=9`\)#\4H72G]"-RB.X[T+)0
M[@`#_$OQ$=M]M]Q+N/4>N^^E"U!.GJLE/]4_CC'2A&(1+RG]D9$2AU_D')8#
MT`#`Y?=P`'@`#YFX;?=I$G3DXS^["ZQ*6DR\S''W%`>XM!R7W;;?*N]#I^@J
M@;ZRU'BZU[=,&M)&DH5+PG&2F'<`_D#)@!U']^^+U\=]P4\=]&J63C'N3"J*
M5YI<F.>`C8>WH(T')8]H!VAZJ0V#;PV#S=@T@5I,PXS^[]T*5',I.'G`[RF$
M`&@9*'QV#U+XH;C\?Q"&_P!^PCH*B?\`$9]R?LC`K!,RD^\QQK"@1)91>@9(
M!$J:AEA.Z?JE\KM'S`,F!!$Y!)XE`.H?#625+*@E#K&HG"<ORP=1(3BDA,O&
M$8/E#CXB8Z)XKRE$S=BK=1PDDHBLD<2G1.D9,#E4*.^X&*!M_M'4D**\+2"%
MA0.6@*E[^4-R_1@2(^$'RJ6"BSL>ZDJ73[<^B`54(N]A5798]10I!\XPKMTR
M(+G(3<#=1-MT'31]FJ2KI5+K"'.2Y3C<VZ"F;*-299F<=?5+-C&9DWS:E5&=
M=RK=$QI!*"[TGI42N"IG]9Y*2*@AZH`[@$1#</#6RJ9K&T-JJ'6RP98'F,O=
M&#3C2SI2CU1Q1UIQ<O:EHB,J4V>Z$6>IKM6HJDFP<I!W/2'5(FFX,;R^IQ$V
MXAK%RGK33Z>JW]+[)0)<92K0E,EPGN<IS'2<%+1,M59J,N;EHW5BU9SO%^1,
M%@,#GS7114,V[-RF^;H(]`T]L[587$K9=2XVD^H)EC\(U53E,4Z5SU^V%-72
M=L.$ZZ-C!0C@]=$K`CL#>>0CB2#\K)L;YR&'NW)_HC]FHW^&=SR9^6>,N?C&
M\:DV\ZLY81P\=/-3XSY)4<AVM!"YBCW"`@`$@DP6*&X``AW;?=OK;>TI_P!0
M,<<4?%4846H4*BK'.$9XSCO'6H?Y<LLX`OF`@I!*.DR('\G?L<D;F*!^\NQM
MQW'^]J3OKA+B%E325Z1GG&F@"1.0,C"D2^1,'1$J[C9V`>1\RW4,#]I+'\AZ
MFOXB+LKA,53]WVB.FR*6Y.MA=.ZDMD<-4I>PQN<>I4$I6/4(,%2M>-K(J[/1
M:I8)59N0I9`]>5<CY29NI"J+MD@()]Q_!OOMIF^Q7-)"JQ;.CA,X^XX^^,FW
M&%>IM&!\X4#S!\G_`-!9(_>?A]1(^/E_BV[]MOAMOX_X-:-?KGUF9>R-VI,Y
MZ%ZOA^'VPIG(3-U6XXX6R-F^XMI!]6\<5U:>?QL0F123DC^:BSCHQB58Y$$W
M4E).DD"G4$J9._N-T`=<OTT2TRPA\,3*$LX_9=Y1Y'?M'N8N--7P[2)ZL(6.
MNS45FMCD&=1</O2+L*[9*\UIT(G'R*K%UWJK(.G""2B9D_FZ&TL@,(#@8=+)
MS47#E:'E)6-BDGSQ&,:+2;ULP([DW1A*TCV9G2J17#YQVF[$B[G4[?E`>NEA
M)QN_EXR*48HR<G'1ZLL^3C8I)\^;M%9&05(=1)@P(X52%\^532.8J*0&.)2B
M(`.PZ()QR/Y%E&LG4G(/&L?&L4%73V0?KI,V3-J@0RBSIVZ<J)(MVS<A!,H<
MYBE*4-])I3R$$%>H9'H&06KI_0+S4+PQ8K@T>NJ?98:RMVKHW>)&[E:'>.DF
MZZA"")`.8.\.H;AL.E``$@!!!$S!R.PS@B1QQ$95OM>I;[*MM3IE-3FI6/CP
M?2YXV0E3*KF?NVQ&<4@TC%/.=''RDCB0@CW'+HPA9PL+&382S%E*13YE*1;]
MNFZ9R4>Y0?,7C98`,BX:.VJBJ#E!4H[E,0PE$.H"(:20A(*%GRIC.ERS"!MV
M1J'4YN3`IV$+9+=7X25?IJF.F@=E'RD@U=."K+$["F*42F,':`]VP:)""#Z!
MN[M,`[@/:(`4-^XHAX@8=@$NX[[A\`TN$$$"T99Q;20<?SGDN@5$&CMO'.C6
M:Y5R"]-(.D2N6K-P$I(MO3NG+<X*$3/L<R8]P!MUT02)C,AEG%T7-PE9D<DT
M"/LME1:.:[7G]RKS.:GF[XGF,G$+%+R";^40?$ZI'1(<J@=2".C"#*#Z)M@`
M1,(=1`1`.F_41-O\`*`#_P`.C"%G!"4RKC-&VEQ^KD6C$OI_+`E(5ML`G;3&
M4)YB:85TS_\`-3**)`)^T$NX2AN`;:,(2#\F83=1'</#PVW'[=A*`Z)"".71
M(01J;H`^._PZ]1'[`^T1T0LX;7#<C(^9Y6W/BRG67Z$I3<-5W,#FVG?-SQKQ
MK8K&K74(-)@"/J4W3=1$53*B?M$O0`^.B0A3+3XPX:2E(R';@\EI)A%M!<-F
MA7,B\;LFYG;U=-LR:@NZ422%=VY5*FD3?N44.!2@)A`-&$8R@CP.8,3VFPN*
ME6<GX\L5J9E7.\K$%=*W+V%L5N8Q%S+P\=).)!,&YBB"FZ8=@AL.B4+C"A[B
M`!OW;]>FW0=NG3J'0?'QT03A.'V8\21EI)1Y/*6.F%S5<(LDZB]NU;;611ZY
M,F5NS+!+R2<J+QR94H)(^5YB@F^4!TA`(@S&.4?//82Q%:90TU8<<T^6ECB4
MRC]Y",E72HE$#?ME?*W5Z[#\V^^I!FZW)AOI,O.);Y`F-*F&5&92(4-A$1<4
MP2BXQ@TCHYNEY"#)B@FU;(I;;=B2*)2$(&WV!IDXM3KG6=.IS.9Q_'&P)2D2
M2)"(Q\/O?Z8\I)ZOR/\`#-IB7GH(3#\A>Z4<A(1`G'H!B'5$I0$?CKN;BV*W
M;R:IL`K$LAP`]40K$VJ\@_)E'%R%B9?$.=H_)4*EV-YIVA8F*W:8J*CY`B;2
M9C%E"_A]6GVB(#U$JNX?AUC9G&KE:?Y<YIU>0G[\X6K"Z>IZB<H=M#9+P1EV
M)CIVPFJ:DC%I@N>/MB+/\PA79?G532]84/-3*?J44Q-OJ!=M]YM2U4S(6$JS
M*3*?NA^E^GJ""H#5XPU7DWG*,OA6&/:&H>0@FKUNK(/FB1B(S+],Q4XZ-C4A
M`IU6;90=Q';8P]-M3EBM;E"%5M5BZ<P3BD<R>,,JVJ"_X3/RPL5M9DPKQ1_E
MIWLA.3L>$:HB4WS'E;$J+I^D`&,(]S2/[BFV\.SQU'4[ANFX0ZG%ILX'F$G`
M^^-Y"6*+0<R([?A3`&C<924RHGV&L-B=*H'V$!5;1R2,>4WQW+YZ9P`=8;K>
M;>KPTB0D,?.,Z!&EJ?"4.*M6*\;WE=-U<*16;&Z2``3<RT2T=N"`7?M*"ZB8
MJ]H;]`WVU"TM;64B=-.ZM*>0)E[H=+::<^=(,&"O56MU-@G%5B#BX".2V[&4
M2S08MPV\!\M`A"F'[QW'6A]QRI7K?4I2ISQ)A4-H;$D``1WO:&VVX^&WXA_R
M[[[ZQD.0C/CJA/\`*%6Q[>L?VJBY49P4A0+E#O*Q:(NPN$FT3)14NB9JLR<+
MKJH%346*;]F8#E.50`$H]P!HA09&8B-CCS9KMQ/Y25'@;+Y`5S9A;(&-+??N
M.MFE)!&4R=AR!QT:,0?XLR*[1.JM9JDC&ODP@9MQV.!%,&JH&$""!"0YOGSA
MB6S?Q8R-`5,BG]1:86&S%BA=`5"N4,G8AFF5_I[=L*1BJ`>;?P0QY_$!2>'`
M0$!VT00T/!628;W$.2F'\SPIU7F&>*>,8BSHIB<#,)3DYERN(&E&;@$E">8]
MQ/5`\DQ3@/IY!ZJ40`P:(R(D/&'S\QL%LN2O&[)N"W-Y5QPKD"%3BHJUD5)Y
M3&71=MY",1D&:CEK^;Q+UVU*B\9]Y?4MCG)\=$(,X1C@CE&%MK'+N,)K$F/,
M09YP)9Z_1,V0N+&L9_3VQN3U]"6I=UJ<C$MFY5H6Q5]QYZ;-R'KXQ0#-U_F*
M`B0'`RA)?<0I&.KUR$]MB&R#`5:::O.25I%7^9(N/>H/V,=BJTK*0*IGP"F#
M9ZX=$6,B.Y3G0`=MPT0D2EPL7$P,/&0]<8L(V$C&2+.+C(Q))"/:,DB`5N@R
M30#R46Z10`"E*':`:((KM<;</Y8Y%1W+FRS=UXO2ENMO(?-U&RY%YIH3ZRY(
MI\-`R[BO4ZIJ2#IVDI7J]'44K)[%BR*W2.5R"X'%01,4C)0`.$3=\6L76C"G
M'?#V);GD-3*UCQW18.HR60UDC(*VP(9J#)I)*$.LX/N=H1,O<)SF/V@83"/7
M1&,1NX6X\X4RKS,]T'+63*17,B/$++C;'+2,LZ03L1#0U?PVA^<E;0ST58]A
M)2R[@?,<IIE<@0H`!PVT1E,@80QBL<>L*QGL=SN2/Y7CI3(4ZRM\Y7<D3SMY
M.W*MS$3G6QPN.DJ_;W2ZDY$L*<P8M&S!!NLFDF1(""`@([D(23G%GF,(JC&1
MJ;E0ZKA-@T(Y54_>*K)MD_-.?IMW**`(F^.XZ(2(<,:5BM\..6R-#O%;HF4*
M!R]SKD'(F#,\@C%2V6J!EVQD=6*6Q7=G2_JIB0KB#8'`0$HT4*@U;E]*N0@@
M01(4REAG$R39^Q7=.F*#UHN]9%2%^T1=(JNFHK@)D#.FY%#+-@7(41)W@4#;
M#MHA([#1!&BFW:.X;_\`)]OP_3H@B,3$RQ'_`+K?+-1(J)S0/&/`,6J8JR9U
MB&EY6:EDDA2W\Q)(R:/<&^P&'2\(R_,]L8]VZK,,B\3X?%4F_>1S/*G(_B]1
M7+R.D5X>42:2.=*0N^-&OVQTW#9^9HS."9B&`P".X#I($_-":\SN/.$L12/!
M"=Q3CRIXYOD/S*Q54JU:JI%DBI\T!)U:]&LT(^DVAB/)EA.145LY(\.X`QB`
M8?G#NTL$R09Q*!F.6L4#B/*<W4"*K6R(QW=92L)HE!18T_'UN1=1!44Q`P**
MA())B4H@/<.P:2,8CR]N+#O&>9XC8)OI(&B7V_7:/B,FW_(EF9Q<OD"9S>_>
MGD[5(2LO)^=.LK##6LJK9-N!TO3%0*F0A0*`:(RU*B4)>7BF;YC&NI*/:/Y,
MRZ<8P<O&Z#N2.U2!5R1@V54*L]4;);'4!,#"F00$=@'1&,=IH@B-_F+0GT18
MX/+$$"J:+@S-A*N4/E%A+,515BW_`'%ZAYP;D$1Z=Y2AOUUV6VJY+[2K:Z<9
M$)]N<1%>TI*^JC*%KI=BI'*3&8URTE)_,4>FDE,()F*C(,)5!$"ISD9N`&%N
MZ`1,(%W+U$@ZAZIBMV[7=5J9;]\.&G&JUO2KYX;-.\*LB-I$Z<'*U^<CC'$&
M[EV?\O>)MQ_#ZE`X"03%W_4$1U/L[KHW$?Q@>K[X:.6^H_PR)PO>'>+L+C9Z
MG=+_`"S"9F(@@NV2)2&;P4&9(H][XQUQ#U3E(H_*8P`4@]0W'41<MP.5P^@H
MP0VK,RQ/A/E#JFH13_Q'C-4-NSID.2SYDJ$IE,`SF#8R(Q4")"B))&2=#Y+Z
M75\.UHB0H]AAZ`F0W^=J>LU$FSV]==4R#A3_`+/Y895+YJGPPT/1QB3JDU5E
M2ZG`5=@``WA8UJS[BAV@LLFD7U#@P?YRZXF./WCKA:I_ZNI758^LDCR,332.
MFV$#@)0:M:8S@:((&B""-D;&E#RY4)B@Y+J\5<J;/HD0EZ]-("NP>II*%61$
MX)F26(J@L4#IG(<IR&#<H@/71!"9X>XI<><!S$S8\38O@ZK9K`Q0BY>T'<S%
M@M#R(;*%5;PQK):).;G$85%4@'*S3<$;%.`&`FX`.B"-\_7_`#10ZV1;"6#W
M&:[5)DD6+"/3N%7J$179,S/:'EK4ZLDC'KJUPSPP@Y"/(Z>$2)N1$XF^4@@B
M<(.,+/B7QZK&+5#0;BXO)">O.3YNO,4XV(G\F7F6<V*X2D>U!!$4HXTH],FV
M3,7<B!"AHA22<X7?*.)<>9HJ2]'R;6F]IJ[EXQD3QJ[N2CCIR$8X(ZCWS61A
MWL=*L7;-P0#IJ(KIG*(>.B$CK,18+Q)@:`>UG$='B*5$RDFK,RY6`O'DC-2Z
MY$TE).<G)9U(3<V^%%(I`5=N%CE(4"@(%#;1`3/$Q\N9^/V&^0T#%5K,M#B;
MS$P,VC8X$CY:2CY""G6[==HG*PDU"OHR:B'OI7*B1CMW"8G3,)3;ATT00I\-
M"QE?B8V"B&P,XN(8-8R.:@HLMZ=DR1(W:H^<X4575%)$@!WG,8YO$1$=QT00
MVS(O"?BUE:Z2&1+QAZ`D;K,MVK2P6*-?V*K/[.W9$\MHE:QJDS"(VD&Z7R$&
M0(Y,"8=F_9\NB%)G#EHN)C82-CX>)9HQ\7%,VT?',6I?+09LFB)4&S5`H#\B
M**)`*4/``#1"05('&%!J\A>I6O5:*B)+)DK^>7UZR1%->TR_Y>6*_,)8PF,"
M[C\N(".^P!V!X:((+`\?<+&Q0WP8..:W_2)KV@WH`-5`KR(%FU+(4"-BK`<`
M"=5,Y_'^]'?[M$$+!V%^7_0Z%^[IMT^&^VB"&S43AQQDQC>BY+I6)("+O"*L
MFM'3;I]/S:D(M,J"K*JUEC8)>5C*NL_,(@J:.0:B8ORB/;TT0LR<([;"?'*G
M84M>;[W%/Y:?NV?<BK9"O-CG7/J'0BA'-8>`K,4B4`2CJU68YL)&K<@=#+*'
M,8QC="$APVB"!H@@B16,,?P=^M>4HFJ1##(5YBH&#MUM;H&+,6")JZ:Z5?82
M+@3B"K>)3<J`B&P=H&'QT0LS*7".>[8ZI&1VD.PO-:C+.SK]E@[C"MY1(RR4
M=:*T]2DH";;E*<@`^B7Z)%43#N!3E`=M$`,L8VMF/:5>G51>V^N1M@=4*TM;
MM3EI%$53UZV,6$C&-)V.$IB>6_0CY9RD4P]P=BQNGQT03@X[?W=/$?CX>.B$
MAL$?PNXOP^1RY9AL0P$'>BV+^;QD8)]8(2*5M0G\T]C<5.*F&=0<S2RW[11R
MHP,JHI\YC";KH@A9Y_&E$M-MH][L-8BY>X8V4G%J+8'B1CR-85LK!.,GE(M4
M#E*D:4CTBI*B(&[B!MH@@\Z((Z"R5F'MD')UV<:E>14NU4:/&Y]MA(H42@=,
M1`?+62,/<4P;"!@`=;&'5T[J7FS):?PQC%Q"74=-7RQ$]DC$.0\"V4;%67,P
MI!M5A-$6R)W`[-'?]G'31$@,5,Q"]#>:4R2WW>.K`H;K17AKZ>H"4U'ZV403
MS#M*[K1/3!LA^:63F#!-O)1=8FUDR@4K]5!RQ54,&_58C94R!E!_T2IAK6_M
M2@4YJ;ZFG]H?=&:;D_\`G`2\OZ83^UYAS!G)VC62J*N&SQ4")UBK-5D4'!C;
M``/1*=9RLDGMN(J'\H/CIY3VNTVQLORDGB5D$^S`1K-34U(T<(>_QSX\$Q@B
M-GLX(.KH^;`BBBD)3MJ^T,&ZC-N?<2*.U@'90X;E*`"!1V'?7)7R]?7+Z#'^
M7&'[4L!.).DI2SZU2U2AV@!L``'P#]/^,=]<^!(2AZ<3.,Z6"!H@@:((&B"!
MH@C7]'=OU\/#\77QZ;_W!H@C4?#IM^+]??\`Z77?[-$$<FB"!H@@:((&B"!H
M@@:((&B"!H@@:((U/^']?QZ]GXMO\O\`@ZZ((!?CX^/W?X]OUOMT01MH@@:(
M(&B"!H@@:((&B"!H@@:((&B",#X#^C1!'4/?[$O_`.'_`+GK^8?V/;?_`+??
MIZ?]'76;4]>.J?A\WPPC!?\`=\/;$>-X_*?SQ;U/_P!/>_U!O[3_`#KZ[?<?
M[5^4?P_F?;\-]]=A3]7I?_H2_P"7^6(]R4_\+XPZ#!_D>A5]/_1?R^NW]+_S
M#?P_VK\R_B>[[=]0=SUZ/5]7_P`S3I_=XPY8EA+IY<)_;"_CMVF_%ML;???N
M^/\`SNS?[/\`)J"1PR_#E]D.L?&.4OX2_P"J'AM]GW=-;1E!&VE@@:((&B"/
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
